{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:12:58Z","timestamp":1783163578083,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04052-3","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T07:01:53Z","timestamp":1727420513000},"page":"389-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of metformin with inositol versus metformin alone in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-6929","authenticated-orcid":false,"given":"Francinny Alves","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0637-0387","authenticated-orcid":false,"given":"Artur","family":"de Oliveira Macena L\u00f4bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-8047","authenticated-orcid":false,"given":"Jorge Henrique Cavalcanti Orestes","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"4052_CR1","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","volume":"2","author":"R Azziz","year":"2016","unstructured":"R. Azziz, E. Carmina, Z. Chen et al. Polycystic ovary syndrome. Nat Rev Dis Primer 2, 16057 (2016). https:\/\/doi.org\/10.1038\/nrdp.2016.57","journal-title":"Nat Rev Dis Primer"},{"key":"4052_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3109\/09513590.2014.887673","volume":"30","author":"D Caserta","year":"2014","unstructured":"D. Caserta, G. Adducchio, S. Picchia et al. Metabolic syndrome and polycystic ovary syndrome: an intriguing overlapping. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 30, 397\u2013402 (2014). https:\/\/doi.org\/10.3109\/09513590.2014.887673","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"4052_CR3","doi-asserted-by":"crossref","unstructured":"Y. Li, C. Chen, Y. Ma., et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS. Life Sci) 228, 167\u2013175 (2019). .","DOI":"10.1016\/j.lfs.2019.04.046"},{"key":"4052_CR4","unstructured":"World Health Organization Polycystic ovary syndrome. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/polycystic-ovary-syndrome. Accessed 25 May 2024"},{"key":"4052_CR5","doi-asserted-by":"publisher","first-page":"121069","DOI":"10.1016\/j.lfs.2022.121069","volume":"310","author":"AA Choudhury","year":"2022","unstructured":"A.A. Choudhury, V.D. Rajeswari, Polycystic ovary syndrome (PCOS) increases the risk of subsequent gestational diabetes mellitus (GDM): A novel therapeutic perspective. Life Sci 310, 121069 (2022). https:\/\/doi.org\/10.1016\/j.lfs.2022.121069","journal-title":"Life Sci"},{"key":"4052_CR6","first-page":"187","volume":"8","author":"R Dumitrescu","year":"2015","unstructured":"R. Dumitrescu, C. Mehedintu, I. Briceag et al. Metformin-clinical pharmacology in PCOs. J Med Life 8, 187\u2013192 (2015)","journal-title":"J Med Life"},{"key":"4052_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/09513590.2022.2119219","volume":"38","author":"X Ji","year":"2022","unstructured":"X. Ji, J. Chen, P. Xu et al. Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: a randomized clinical trial. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 38, 856\u2013860 (2022). https:\/\/doi.org\/10.1080\/09513590.2022.2119219","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"4052_CR8","doi-asserted-by":"publisher","first-page":"CD013505","DOI":"10.1002\/14651858.CD013505","volume":"12","author":"A Sharpe","year":"2019","unstructured":"A. Sharpe, L.C. Morley, T. Tang et al. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev 12, CD013505 (2019). https:\/\/doi.org\/10.1002\/14651858.CD013505","journal-title":"Cochrane Database Syst Rev"},{"key":"4052_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/humrep\/deh588","volume":"20","author":"D Cibula","year":"2005","unstructured":"D. Cibula, M. Fanta, J. Vrbikova et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod Oxf Engl 20, 180\u2013184 (2005). https:\/\/doi.org\/10.1093\/humrep\/deh588","journal-title":"Hum Reprod Oxf Engl"},{"key":"4052_CR10","doi-asserted-by":"publisher","first-page":"1979654","DOI":"10.1155\/2016\/1979654","volume":"2016","author":"D Garg","year":"2016","unstructured":"D. Garg, R. Tal, Inositol Treatment and ART Outcomes in Women with PCOS. Int J Endocrinol 2016, 1979654 (2016). https:\/\/doi.org\/10.1155\/2016\/1979654","journal-title":"Int J Endocrinol"},{"key":"4052_CR11","doi-asserted-by":"crossref","unstructured":"M. Januszewski, T. Issat, A.A. Jakimiuk,et al. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol 90, 7\u201310 (2019). .","DOI":"10.5603\/GP.2019.0002"},{"key":"4052_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12020-017-1442-y","volume":"59","author":"L Zeng","year":"2018","unstructured":"L. Zeng, K. Yang, Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine 59, 30\u201338 (2018). https:\/\/doi.org\/10.1007\/s12020-017-1442-y","journal-title":"Endocrine"},{"key":"4052_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"M.J. Page, J.E. McKenzie, P.M. Bossuyt et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4052_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81, 19\u201325 (2004). https:\/\/doi.org\/10.1016\/j.fertnstert.2003.10.004","journal-title":"Fertil Steril"},{"key":"4052_CR15","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","volume":"21","author":"D Ferriman","year":"1961","unstructured":"D. Ferriman, J.D. Gallwey, Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21, 1440\u20131447 (1961). https:\/\/doi.org\/10.1210\/jcem-21-11-1440","journal-title":"J Clin Endocrinol Metab"},{"key":"4052_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1046\/j.1365-4362.1997.00099.x","volume":"36","author":"A Doshi","year":"1997","unstructured":"A. Doshi, A. Zaheer, M.J. Stiller, A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 36, 416\u2013418 (1997). https:\/\/doi.org\/10.1046\/j.1365-4362.1997.00099.x","journal-title":"Int J Dermatol"},{"key":"4052_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019). https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4052_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"J.P.T. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327, 557\u2013560 (2003). https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"4052_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"S. Balduzzi, G. R\u00fccker, G. Schwarzer, How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22, 153\u2013160 (2019). https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"4052_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2307\/2336502","volume":"70","author":"KKG Lan","year":"1983","unstructured":"K.K.G. Lan, D.L. DeMets, Discrete Sequential Boundaries for Clinical Trials. Biometrika 70, 659\u2013663 (1983). https:\/\/doi.org\/10.2307\/2336502","journal-title":"Biometrika"},{"key":"4052_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/09513590.2018.1549656","volume":"35","author":"A Agrawal","year":"2019","unstructured":"A. Agrawal, R. Mahey, G. Kachhawa et al. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 35, 511\u2013514 (2019). https:\/\/doi.org\/10.1080\/09513590.2018.1549656","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"4052_CR22","doi-asserted-by":"publisher","first-page":"e15510","DOI":"10.7759\/cureus.15510","volume":"13","author":"A Bahadur","year":"2021","unstructured":"A. Bahadur, H. Arora, A.K. Ravi et al. Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy of metformin with myoinositol plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial. Cureus 13, e15510 (2021). https:\/\/doi.org\/10.7759\/cureus.15510","journal-title":"Cureus"},{"key":"4052_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4103\/jhrs.JHRS_59_17","volume":"11","author":"N Chhabra","year":"2018","unstructured":"N. Chhabra, S. Malik, Effect of insulin sensitizers on raised serum anti-mullerian hormone levels in infertile women with polycystic ovarian syndrome. J Hum Reprod Sci 11, 348\u2013352 (2018). https:\/\/doi.org\/10.4103\/jhrs.JHRS_59_17","journal-title":"J Hum Reprod Sci"},{"key":"4052_CR24","doi-asserted-by":"publisher","unstructured":"Alnisani Z.A., Abdulrida M.K. (2023) Effectiveness of Myoinositol alone or in Companion with Metformin in Improving Hormonal, Metabolic, and Clinical Features of PCOS Women. Iraqi J Pharm Sci P-ISSN 1683 - 3597 E-ISSN 2521 - 3512 32:61\u201373 https:\/\/doi.org\/10.31351\/vol32issSuppl.pp61-73","DOI":"10.31351\/vol32issSuppl.pp61-73"},{"key":"4052_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/cen.14931","volume":"99","author":"R Nazirudeen","year":"2023","unstructured":"R. Nazirudeen, S. Sridhar, R. Priyanka et al. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. Clin Endocrinol (Oxf) 99, 198\u2013205 (2023). https:\/\/doi.org\/10.1111\/cen.14931","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4052_CR26","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.18203\/2320-1770.ijrcog20202345","volume":"9","author":"SS Thakur","year":"2020","unstructured":"S.S. Thakur, S. Anjum, S.S. Siddiqui, Randomised controlled trial: comparing effects of metformin versus myoinositol versus metformin and myoinositol on ovarian functions and metabolic factors in polycystic ovarian syndrome. Int J Reprod Contracept Obstet Gynecol 9, 2542\u20132549 (2020). https:\/\/doi.org\/10.18203\/2320-1770.ijrcog20202345","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"4052_CR27","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1210\/js.2019-00078","volume":"3","author":"SF Witchel","year":"2019","unstructured":"S.F. Witchel, S.E. Oberfield, A.S. Pe\u00f1a, Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc 3, 1545\u20131573 (2019). https:\/\/doi.org\/10.1210\/js.2019-00078","journal-title":"J Endocr Soc"},{"key":"4052_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s43043-021-00085-0","volume":"26","author":"M Mitra\u0161inovi\u0107-Bruli\u0107","year":"2021","unstructured":"M. Mitra\u0161inovi\u0107-Bruli\u0107, M. Buljan, D. Suljevi\u0107, Association of LH\/FSH ratio with menstrual cycle regularity and clinical features of patients with polycystic ovary syndrome. Middle East Fertil Soc J 26, 40 (2021). https:\/\/doi.org\/10.1186\/s43043-021-00085-0","journal-title":"Middle East Fertil Soc J"},{"key":"4052_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01436-x","volume":"17","author":"MZ Md Muslim","year":"2024","unstructured":"M.Z. Md Muslim, A. Mohammed Jelani, N. Shafii et al. Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis. J Ovarian Res 17, 106 (2024). https:\/\/doi.org\/10.1186\/s13048-024-01436-x","journal-title":"J Ovarian Res"},{"key":"4052_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"E. Diamanti-Kandarakis, A. Dunaif, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33, 981\u20131030 (2012). https:\/\/doi.org\/10.1210\/er.2011-1034","journal-title":"Endocr Rev"},{"key":"4052_CR31","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.biochi.2013.05.011","volume":"95","author":"ML Croze","year":"2013","unstructured":"M.L. Croze, C.O. Soulage, Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95, 1811\u20131827 (2013). https:\/\/doi.org\/10.1016\/j.biochi.2013.05.011","journal-title":"Biochimie"},{"key":"4052_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/ph14060504","volume":"14","author":"R Gambioli","year":"2021","unstructured":"R. Gambioli, G. Forte, G. Buzzaccarini et al. Myo-inositol as a key supporter of fertility and physiological gestation. Pharm Basel Switz 14, 504 (2021). https:\/\/doi.org\/10.3390\/ph14060504","journal-title":"Pharm Basel Switz"},{"key":"4052_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0021-9258(18)64820-3","volume":"226","author":"H Eagle","year":"1957","unstructured":"H. Eagle, V.I. Oyama, M. Levy, A.E. Freeman, Myo-Inositol as an essential growth factor for normal and malignant human cells in tissue culture. J Biol Chem 226, 191\u2013205 (1957)","journal-title":"J Biol Chem"},{"key":"4052_CR34","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1096\/fj.05-4192fje","volume":"19","author":"C Jf","year":"2005","unstructured":"C. Jf, L. Mk, L. Jw et al. Sodium\/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves. FASEB J Off Publ Fed Am Soc Exp Biol 19, 1887\u20131889 (2005). https:\/\/doi.org\/10.1096\/fj.05-4192fje","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"4052_CR35","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/jbmr.240","volume":"26","author":"Z Dai","year":"2011","unstructured":"Z. Dai, S.K. Chung, D. Miao et al. Sodium\/myo-inositol cotransporter 1 and myo-inositol are essential for osteogenesis and bone formation. J Bone Miner Res Off J Am Soc Bone Miner Res 26, 582\u2013590 (2011). https:\/\/doi.org\/10.1002\/jbmr.240","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"4052_CR36","doi-asserted-by":"publisher","unstructured":"Sharon P.M., P M, Manivannan A., et al. The effectiveness of myo-inositol in women with polycystic ovary syndrome: a prospective clinical study. Cureus 16:e53951 https:\/\/doi.org\/10.7759\/cureus.53951","DOI":"10.7759\/cureus.53951"},{"key":"4052_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12958-023-01055-z","volume":"21","author":"D Greff","year":"2023","unstructured":"D. Greff, A.E. Juh\u00e1sz, S. V\u00e1ncsa et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol RBE 21, 10 (2023). https:\/\/doi.org\/10.1186\/s12958-023-01055-z","journal-title":"Reprod Biol Endocrinol RBE"},{"key":"4052_CR38","unstructured":"Rosa A.D. (2022) Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. In: Eur. Rev. https:\/\/www.europeanreview.org\/article\/28322. Accessed 25 May 2024"},{"key":"4052_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/09513590.2016.1236078","volume":"33","author":"F Fruzzetti","year":"2017","unstructured":"F. Fruzzetti, D. Perini, M. Russo et al. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 33, 39\u201342 (2017). https:\/\/doi.org\/10.1080\/09513590.2016.1236078","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"4052_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-021-01207-7","volume":"18","author":"H Zhao","year":"2021","unstructured":"H. Zhao, C. Xing, J. Zhang, B. He, Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health 18, 171 (2021). https:\/\/doi.org\/10.1186\/s12978-021-01207-7","journal-title":"Reprod Health"},{"key":"4052_CR41","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/metabo12121183","volume":"12","author":"P Ravn","year":"2022","unstructured":"P. Ravn, F. Gram, M.S. Andersen, D. Glintborg, Myoinositol vs. metformin in women with polycystic ovary syndrome: a randomized controlled clinical trial. Metabolites 12, 1183 (2022). https:\/\/doi.org\/10.3390\/metabo12121183","journal-title":"Metabolites"},{"key":"4052_CR42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40618-021-01691-5","volume":"45","author":"V Soldat-Stankovi\u0107","year":"2022","unstructured":"V. Soldat-Stankovi\u0107, S. Popovi\u0107-Peji\u010di\u0107, S. Stankovi\u0107 et al. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. J Endocrinol Invest 45, 583\u2013595 (2022). https:\/\/doi.org\/10.1007\/s40618-021-01691-5","journal-title":"J Endocrinol Invest"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04052-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04052-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:27:45Z","timestamp":1739190465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04052-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["4052"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04052-3","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}